Nebenwirkungen · Kisplyx
Kisplyx 4 mg hard capsules Kisplyx 10 mg hard capsules · Abschnitt 4.8 · PDF-Seite 18
HOS-225036 · Präparat HOS-217386
In the pooled RCC population treated with lenvatinib and everolimus, fistula formation events were reported in 1.0% of patients (0.5% were Grade ≥3). In patients where data on individual drug modifications were collected, 0.8% of patients with GI perforations had dose modifications of lenvatinib (0.8% interruption) and led to permanent treatment discontinuation in 0.4% of patients. The median time to onset of fistula formation events in lenvatinib plus everolimus-treated patients was 3.7 months.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-26T17:24:00Z · SHA-256 a44a00845e1c56c73ff53a9371d99e0ff78be7df90f4e83eb5595124e9e6b142 · Passage 558ad6c4004d9a8602d12f75ad0241c085249ad6b13671d1a59ea0c6ceb962bb · Zeichen 28723–29223 im Abschnitt